Latest Partnerships News

Australian Strategic Materials secures A$50.8 million via share placement to fund Korean plant expansion and advance US metals project, while navigating complex supply chain and funding risks.

ASM Limited has raised A$55 million to accelerate production capacity at its Korean Metals Plant and expand its footprint in the rare earths sector, responding to growing global demand and geopolitical supply chain pressures.

Raiz Invest has hit a record $2 billion in funds under management, driven by strong customer growth and innovative product launches. The fintech’s latest quarter also saw strategic partnerships expand its market reach.

Horizon Gold advances its Gum Creek project with significant gold intercepts from water bore drilling and launches an AI-powered exploration platform, while maintaining its feasibility study timeline and securing $12 million in fresh capital.

EPX Limited reported a net increase in Annual Contract Value to $18 million and a steady rise in Annual Recurring Revenue to $15.7 million for Q3 2025, driven by new contracts in the UAE healthcare sector and Australian commercial properties.

Metal Powder Works Limited (MPW) has landed a $1 million contract with the US Navy for its innovative expeditionary DirectPowder™ unit, while expanding its alloy portfolio and customer base amid a $15 million capital raise.

Noronex Limited has secured a significant earn-in agreement with South32, enabling a A$5 million exploration program at the Cgae Cgae Copper Project in Botswana. This deal expands their strategic alliance and sets the stage for extensive drilling activity in the Kalahari Copper Belt.

Prospech Limited reports steady progress on rare earth element metallurgy at its Korsnäs project and promising gold-silver drill results in Slovakia, backed by a fully subscribed $2.1 million capital raising.

Wide Open Agriculture has developed a novel lupin protein milk formulation that overcomes longstanding technological hurdles, lodging a patent to protect its innovation and gearing up for global commercialisation.

Algorae Pharmaceuticals has signed a binding term sheet with India’s Cadila Pharmaceuticals to introduce two generic medicines targeting cardiovascular and metabolic disorders in Australia and New Zealand.

Race Oncology showcased compelling preclinical data at ESMO 2025 revealing that their drug RC220, combined with doxorubicin, not only shields the heart from toxicity but also boosts anticancer effects, supporting ongoing clinical trials.

Orthocell has boosted its investment in Marine Biomedical to secure exclusive global distribution rights for PearlBone™, an innovative bone substitute nearing FDA approval, enhancing its regenerative medicine portfolio.